IMR Press / RCM / Volume 22 / Issue 3 / DOI: 10.31083/j.rcm2203065
Open Access Letter to the Editor
Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19
Show Less
1 National Cardiology Research Center, 121552 Moscow, Russia
2 Cardiology Division, Central Clinical Hospital of Presidential Administration, 121359 Moscow, Russia
3 Institute of Physics and Technology, 141701 Moscow, Russia
4 Neurology, Johns Hopkins University, Baltimore, MD 21794, USA

Academic Editor: Peter A. McCullough

Rev. Cardiovasc. Med. 2021, 22(3), 549–551; https://doi.org/10.31083/j.rcm2203065
Submitted: 31 August 2021 | Revised: 2 September 2021 | Accepted: 8 September 2021 | Published: 24 September 2021
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Figures
Fig. 1.
Share
Back to top